This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Stocks to Buy as Companies Speed Up Vaccine Production
by Ritujay Ghosh
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Bull of the Day: Quidel (QDEL)
by Kevin Cook
Multiple FDA approvals for new 15-minute COVID-19 antigen tests have estimates and shares rising sharply
Invest in the Future With Megatrend ETFs
by Neena Mishra
These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.
Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
New GERM ETF Launched to Tap the Growing Biotech Sector
by Sweta Killa
GERM invests in the hottest emerging biotechnology trends.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $63.31 in the latest trading session, marking a -1.6% move from the prior day.
Novavax (NVAX) Up More Than 1200% Year to Date: Here's Why
by Zacks Equity Research
Novavax's (NVAX) coronavirus vaccine candidate NVX-CoV2373 enters clinical studies. The company also plans to file a BLA on its influenza vaccine candidate, NanoFlu.
Vaxart Gets New CEO, Focuses on Coronavirus Vaccine Program
by Zacks Equity Research
Vaxart (VXRT) management names Andrei Floroiu as its next chief executive officer with immediate effect. Stock appreciates on this news.
3 Big Biotechs Poised for Growth Amid Coronavirus Pandemic
by Ekta Bagri
We highlight a few leading players from the biotech sector, who are likely to see a good run as the year progresses.
Economic Recovery Debate Heats Up: 4 Sectors Holding Ground
by Urmimala Biswas
Here we discuss four sectors for which COVID-19 has opened up enormous growth prospects.
AstraZeneca to Supply 400M Coronavirus Vaccine Doses in Europe
by Zacks Equity Research
AstraZeneca's (AZN) supply deals will require it to produce 2 billion doses of the vaccine, if it is successfully developed.
Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain
by Sweta Jaiswal, FRM
Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $60.20 in the latest trading session, marking a +0.22% move from the prior day.
J&J to Begin Human Study on Coronavirus Vaccine in July
by Zacks Equity Research
J&J's (JNJ) goal is to supply more than 1 billion doses of the vaccine globally if it proves to be safe and effective.
Fed Sparks Economic Concerns: Winning Investment Strategies
by Sanghamitra Saha
The Fed now expects the U.S. unemployment rate to hit 9.3% this year and sees American GDP falling by 6.5% in 2020.
Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus
by Ritujay Ghosh
Several drugmakers have started ramping up production, anticipating huge demand if the candidates prove successful.
Moderna (MRNA) Up 9.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax Clinches $60M Defense Contract for Coronavirus Vaccine
by Zacks Equity Research
Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.
AstraZeneca to Ensure Equal Access to Coronavirus Vaccine
by Zacks Equity Research
AstraZeneca (AZN) signs three new supply deals to ensure broad and equitable global access to its COVID-19 vaccine following its successful development.
Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report
by Kinjel Shah
The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.
AstraZeneca Inks Deal to Develop RMP Inhibitors for Cancer
by Zacks Equity Research
AstraZeneca (AZN) signs an oncology agreement with Accent Therapeutics to develop novel therapies targeting RNA-modifying proteins for treating cancer.
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
5 Top Stocks Up 100%+ in May With More Room to Run
by Tirthankar Chakraborty
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
Glaxo Plans to Make 1B Doses of Coronavirus Vaccine Adjuvant
by Zacks Equity Research
Glaxo (GSK) set to enhance its manufacturing capacity to make 1 billion doses of its pandemic vaccine adjuvant, which can be used to improve efficacy and scale up of multiple COVID-19 vaccines.
5 Reasons to Bet on Growth ETFs
by Sanghamitra Saha
A few upbeat developments on the vaccine front, unprecedented economic help, reopening of economies and a few bullish economic datapoints should facilitate growth stocks ahead.